Treatment of benign bone lesions with an injectable bone filler material

ISRCTN ISRCTN10903007
DOI https://doi.org/10.1186/ISRCTN10903007
Secondary identifying numbers 1218/2016
Submission date
14/07/2022
Registration date
21/07/2022
Last edited
21/07/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Benign bone lesions are areas of bone that are changed or damaged but are not cancerous. The established surgical treatments of benign bone lesions consist of open and minimally invasive surgery. In recent years, injectable and moldable bone graft materials have been developed for filling fluid-filled bone lesions in minimally invasive surgery. This study aims to retrospectively assess minimally invasive and open surgeries using an injectable bone graft material.

Who can participate?
Patients treated with an injectable bone graft material for benign bone lesions with a complete set of data and a postoperative follow-up of at least 1 year

What does the study involve?
The clinical records and x-ray images of patients are assessed.

What are the possible benefits and risks of participating?
Although there are no direct benefits for reviewed patients, future patients and treating surgeons might benefit from the conclusions made from this retrospective data analysis.

Where is the study run from?
Medical University of Vienna (Austria)

When is the study starting and how long is it expected to run for?
February 2016 to March 2022

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Catharina Chiari, catharina.chiari@meduniwien.ac.at

Contact information

Prof Catharina Chiari
Principal Investigator

Department of Orthopedics and Trauma Surgery
Medical University of Vienna
Währinger Gürtel 18-20
Vienna
1090
Austria

Phone +43 (0)14040040830
Email catharina.chiari@meduniwien.ac.at

Study information

Study designRetrospective single-center data analysis
Primary study designObservational
Secondary study designCase series
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet
Scientific titleTreatment of benign bone lesions with an injectable biphasic bone substitute
Study objectivesInjectable biphasic bone graft substitutes represent a modern alternative for conventional options of bone defect filling, as they further open the possibilities of percutaneous cavity reconstruction. Although recent studies showed good surgical outcomes after treatment with injectable biphasic bone graft substitutes, mid-term follow-ups are still missing.
Ethics approval(s)Approved 27/07/2016, Ethics Committee of the Medical University of Vienna (Borschkegasse 8b/E06, Vienna, Austria; +43 (0)1 40400 21470; ethik-kom@meduniwien.ac.at), ref: 1218/2016
Health condition(s) or problem(s) studiedBenign bone lesions
InterventionAfter the approval of the local ethics committee, a retrospective data analysis of the in-house software system will identify patients who were treated with Cerament® Bone Void Filler (Bonesupport™, Lund, Sweden) for benign bone lesions. After the application of inclusion criteria, patients will be included in this retrospective analysis.

Research questions:
1. What was the treatment failure rate after surgical treatment with a biphasic ceramic bone substitute?
2. How did the cavity morphology change in the postoperative course?
3. What were the treatment-specific complications?
Intervention typeProcedure/Surgery
Primary outcome measureLocal recurrences identified by retrospective analysis of patient charts in the timeframe between surgery and last follow-up at the outpatient clinic
Secondary outcome measures1. Postoperative cavity morphology changes assessed using x-rays at 6 weeks, 3 months, 6 months, 12 months, 18 months and at the last follow-up after surgery (MRI will be assessed in cases of suspected recurrence or incomplete cavity consolidation)
3. Postoperative complications assessed by review of patient charts in the timeframe between surgery and last follow-up at the outpatient clinic
Overall study start date17/02/2016
Completion date27/03/2022

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants18
Total final enrolment18
Key inclusion criteriaPatients who:
1. Received treatment with a ceramic biphasic bone substitute
2. For benign bone tumors and tumor-like lesions
3. With a complete set of retrospective information, including surgical protocols, X-rays, patient dismission letters and outpatient clinic protocols
4. With a minimum follow-up of 1 year after surgery
Key exclusion criteria1. Inconclusive data with missing surgical or histological reports
Date of first enrolment27/07/2016
Date of final enrolment18/12/2021

Locations

Countries of recruitment

  • Austria

Study participating centre

Medical University of Vienna
Währinger Gürtel 18-20
Vienna
1090
Austria

Sponsor information

Medical University of Vienna
University/education

Währinger Gürtel 18-20
Vienna
1090
Austria

Phone +43 (0)14040040820
Email reinhard.windhager@meduniwien.ac.at
Website http://www.meduniwien.ac.at/homepage/1/homepage/
ROR logo "ROR" https://ror.org/05n3x4p02

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date27/03/2023
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planSubmitted manuscript to a peer-reviewed journal
IPD sharing planThe datasets generated and analysed during the current study are available upon reasonable request from Ao.Univ.-Prof. Dr Catharina Chiari (catharina.chiari@meduniwien.ac.at). Type of data: retrospective data including demographic parameters, surgery-specific data, data on preoperative and postoperative imaging. The pseudonymized data will become available on reasonable request after study publication for members of the scientific community.

Editorial Notes

19/07/2022: Trial's existence confirmed by the Ethics Committee of the Medical University of Vienna.